Home > Newsletters > FDAnews Drug Daily Bulletin > Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
FDAnews Drug Daily Bulletin
Aug. 6, 2012 | Vol. 9 No. 153
Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
Pfizer is trumpeting its exclusive rights to one of its best-selling products until late 2018 after a Delaware district court upheld its patents on pain and seizure drug Lyrica. A Wilmington, Del., federal judge ruled Teva Pharmaceuticals and other generic-drug applicants would infringe on Lyrica’s (pregabalin) patents and enjoined them from making or selling their products until then.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.